<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudoxanthoma elasticum</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudoxanthoma elasticum</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pseudoxanthoma elasticum</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lionel Bercovitch, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3816969922"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pseudoxanthoma elasticum (PXE; MIM #264800) is a rare, late-onset, heritable disorder characterized by ectopic mineralization and fragmentation of elastic fibers in the skin, eye, vascular, and gastrointestinal system [<a href="#rid1">1-3</a>]. PXE is caused by homozygous or compound heterozygous mutations in the <em>ABCC6</em> gene, which encodes the cellular transmembrane transport protein ABCC6. In this chapter, we will review the etiology and pathogenesis, clinical and histopathologic features, complications, diagnosis, and treatment of PXE. Other inherited disorders of connective tissue are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117132.html" rel="external">"Focal dermal hypoplasia (Goltz syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/89916.html" rel="external">"Overview of the management of Ehlers-Danlos syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8151.html" rel="external">"Management of Marfan syndrome and related disorders"</a>.)</p><p></p><p class="headingAnchor" id="H2846969863"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The exact prevalence of PXE is unknown. It has been estimated to be 1:25,000 to 1:100,000 in the general population [<a href="#rid4">4</a>], but it may be much higher among the Afrikaner population in South Africa due to a founder effect [<a href="#rid5">5</a>]. More precise estimates cannot be made due to the highly variable expressivity of PXE, as some patients have minimal to no skin lesions despite having ocular or cardiovascular manifestations. The carrier rate for pathogenic <em>ABCC6 </em>variants has been estimated to be between 1:80 and 1:150 [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2130512996"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>PXE is an autosomal recessive disorder with complete penetrance caused by homozygous or compound heterozygous pathogenic variants in the <em>ABCC6</em> gene on chromosome 16p13.1, encoding the ATP-binding cassette, subfamily C, member 6 (ABCC6) [<a href="#rid7">7</a>]. However, two incompletely penetrant pathogenic variants have been found [<a href="#rid8">8</a>]. Earlier suggestions of autosomal dominant inheritance in families with two affected individuals in subsequent generations have been discounted by genetic analysis and shown to reflect pseudodominance in consanguineous families [<a href="#rid9">9</a>]. The majority (approximately 90 percent) of patients with the classic form of PXE harbor pathogenic inactivating variants in the <em>ABCC6</em> gene, which is expressed primarily in the liver and, to some extent, in the proximal tubules of the kidneys [<a href="#rid10">10</a>].</p><p>However, there is genetic heterogeneity. Rare cases with a PXE phenotype harbor pathogenic variants in the <em>ENPP1</em> gene (encoding the ectonucleotide pyrophosphatase/phosphodiesterase 1) and genetically overlap with another ectopic mineralization disorder, the generalized arterial calcification of infancy (GACI; MIM #208000), which is inherited in an autosomal recessive mode and is caused by mutations in <em>ENPP1</em> [<a href="#rid11">11-14</a>].</p><p>While patients with PXE characteristically develop the earliest clinical signs at the end of the first decade or during the second decade of life, patients with PXE due to <em>ENPP1</em> mutations are often diagnosed during the first year of life. In contrast with PXE, classic GACI manifests with extremely severe vascular involvement, often diagnosed prenatally by ultrasound at the 14<sup>th</sup> to 15<sup>th</sup> week of gestation. Many of these patients die of cardiovascular complications during the first year of life. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Autosomal recessive hypophosphatemic rickets'</a>.)</p><p>In the spectrum of heritable ectopic mineralization disorders, arterial calcification due to deficiency in CD73 (ACDC; MIM#211800) manifests primarily with vascular calcification in the lower extremities and periarticular calcification in older adults [<a href="#rid13">13,15</a>]. This ultrarare autosomal recessive disorder is caused by inactivating mutations in <em>NT5E</em>, encoding the ecto-5-prime-nucleotidase.</p><p class="headingAnchor" id="H2711447679"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Under physiologic conditions, the gene product of <em>ABCC6</em> (ATP-binding cassette, subfamily C, member 6 [ABCC6]) is an efflux transporter protein expressed primarily in the basolateral surface of hepatocytes and is not present in tissues demonstrating ectopic mineralization or in the principal cells of such tissues (eg, dermal fibroblasts). Physiologically, ABCC6 facilitates transport of ATP from the hepatocytes through the plasma membrane, and ATP is rapidly converted in the extracellular milieu to AMP and inorganic pyrophosphate (PPi) by the ectonucleotide pyrophosphatase/phosphodiesterase (1 ENPP1) [<a href="#rid16">16</a>]. The enzyme protein encoded by <em>NT5E</em> (the ecto-5-prime-nucleotidase CD73) further degrades AMP to adenosine and inorganic phosphate (Pi). Pathogenic variants in the <em>ABCC6</em>, <em>ENPP1</em>, and <em>NT5E</em> genes cause ectopic mineralization for the classic forms of PXE, generalized arterial calcification of infancy (GACI), and arterial calcification due to deficiency in CD73 (ACDC), respectively, which share some metabolic and clinical features (notably, reduced levels of circulating PPi and vascular involvement) [<a href="#rid13">13</a>].</p><p>In patients with PXE, the PPi plasma levels are reduced to approximately 30 percent compared with the control levels [<a href="#rid17">17</a>]. However, plasma levels of PPi in PXE do not correlate with either genotype or phenotype [<a href="#rid18">18,19</a>]. By contrast, in patients with GACI due to loss-of-function mutations in the <em>ENPP1</em> gene, the plasma PPi levels are essentially zero as reflected by its very low levels in urine [<a href="#rid20">20</a>]. Plasma PPi has a relatively short half-life and is physiologically degraded by tissue-nonspecific alkaline phosphatase (TNAP), which is downregulated by adenosine [<a href="#rid21">21</a>]. Thus, in patients with ACDC with deficient conversion of AMP to adenosine and Pi, the plasma adenosine levels are reduced, thus resulting in activation of TNAP and subsequent reduction in plasma PPi levels. In ACDC, the patients' plasma PPi levels have not been reported, but in a mouse model (<em>Nt5e</em><em><sup>-/-</sup></em>), the serum PPi levels are significantly reduced [<a href="#rid22">22</a>].</p><p>Collectively, in the three heritable ectopic mineralization disorders (ie, PXE, GACI, and ACDC), the unifying pathomechanistic feature is the reduced circulating PPi level [<a href="#rid13">13,23</a>]. Since PPi is physiologically a powerful antimineralization factor, reduced PPi levels allow ectopic mineralization to ensue in elastin-rich tissues, including skin, eyes, and the arterial blood vessels.</p><p>In general terms, the level of circulating PPi correlates with the severity of the disease:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with GACI with essentially zero plasma levels of PPi, the ectopic mineralization is extremely severe, resulting in considerable early mortality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In PXE (with the residual PPi levels being approximately 30 percent of the controls), the ectopic mineralization is variable and of late onset, the disease is slowly progressive, and the actual lifespan is rarely impacted. However, there is considerable inter- and intra-familial phenotypic heterogeneity, even in individuals with the same mutations. It has been suggested that the influence of modifier genes, epigenetic factors, and lifestyle variables (eg, exercise and diet) might explain such variability in the severity of the disease [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with ACDC, only slightly reduced plasma PPi levels would explain the relatively mild disease manifesting in older adults.</p><p></p><p class="headingAnchor" id="H604696820"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The pathologic changes of PXE are found primarily in the dermis, Bruch's membrane of the retina, and internal elastic lamina of medium-sized arteries. Therefore, clinical manifestations occur in the skin, eyes, and cardiovascular system, as well as organs supplied by affected arteries [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2609225019"><span class="h2">Age at presentation</span><span class="headingEndMark"> — </span>Early cutaneous and ocular findings are subtle and are in most cases not noticed until the second or third decades of life, although they have been described in children younger than 10 years [<a href="#rid4">4,25,26</a>]. PXE presents before the age of 15 years in approximately 15 percent of cases, but the diagnosis is often delayed by several years, especially in male patients [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H708923195"><span class="h2">Skin</span><span class="headingEndMark"> — </span>The primary lesion in the skin is a papule that may appear yellowish or darker than the person's natural skin tone, initially located on the side of the neck (<a class="graphic graphic_picture graphicRef129952 graphicRef129957" href="/z/d/graphic/129952.html" rel="external">picture 1A-B</a>) and later in the axillae (<a class="graphic graphic_picture graphicRef129953" href="/z/d/graphic/129953.html" rel="external">picture 2</a>) and other flexural areas (eg, antecubital fossa, popliteal fossa, groin), chest, and abdomen [<a href="#rid25">25</a>]. The labial, vaginal, anal, and gastric mucosae may show similar lesions. The skin papules eventually coalesce to form plaques, and ultimately the affected skin becomes lax and redundant (<a class="graphic graphic_picture graphicRef129954 graphicRef129958" href="/z/d/graphic/129954.html" rel="external">picture 3A-B</a>). There is no relationship between the severity of skin manifestations and ocular or cardiovascular manifestations. In some patients, skin findings can be subtle or undetectable [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3473536766"><span class="h2">Eye</span><span class="headingEndMark"> — </span>Angioid streaks, named because of their resemblance to retinal blood vessels, are the most characteristic eye finding in PXE (<a class="graphic graphic_picture graphicRef129955" href="/z/d/graphic/129955.html" rel="external">picture 4</a>) [<a href="#rid27">27</a>]. These are often not seen until late adolescence or the third decade. The earliest ocular manifestation, often seen in childhood, is "peau d'orange" of the retina, a fine, yellowish pebbling of the ocular fundus resulting from dystrophic calcification the Bruch's membrane, the elastic layer that separates the retinal pigmented epithelium from the choroid (<a class="graphic graphic_picture graphicRef129956" href="/z/d/graphic/129956.html" rel="external">picture 5</a>). Progressing calcification results in breaks in Bruch's membrane that form around the optic papilla and radiate peripherally, exposing the choriocapillaris, with a characteristic "angioid" appearance. The color of the streaks may vary from red to black, depending on the amount of pigmentation in the choroid. Although present in most patients with PXE by the third decade, angioid streaks remain asymptomatic until neovascularization occurs and, unless affecting the perifoveal area, do not affect visual acuity [<a href="#rid27">27</a>].</p><p>Eventually, in most patients, fragile new vessels grow through the angioid streaks ("neovascularization"). Leakage of serum or blood from these vessels focally detaches the overlying retinal photoreceptors, causing distorted vision (<a class="graphic graphic_picture graphicRef129960" href="/z/d/graphic/129960.html" rel="external">picture 6</a>). This distortion can be documented with an Amsler grid (<a class="graphic graphic_figure graphicRef56604" href="/z/d/graphic/56604.html" rel="external">figure 1</a>), which provides an early diagnostic tool for the patient. Indeed, all patients with angioid streaks should have an Amsler grid and use it on a regular basis to detect early distortions in central vision. Lesions that leak or bleed heal with irreversible scarring (<a class="graphic graphic_picture graphicRef129961" href="/z/d/graphic/129961.html" rel="external">picture 7</a>) which, when involving the macula, can lead to permanent central vision loss and legal blindness.</p><p class="headingAnchor" id="H3538690280"><span class="h2">Cardiovascular system</span><span class="headingEndMark"> — </span>Cardiovascular manifestations of PXE result from progressive narrowing of small- and medium-sized arteries due to elastorrhexis and calcification of dystrophic elastic fibers in the internal elastic lamina and tunica media of these vessels [<a href="#rid4">4,28</a>]. These changes are associated with peripheral arterial disease independent of other known cardiovascular risk factors [<a href="#rid29">29,30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Diminution or loss of peripheral pulses, including radial pulses, and early onset of intermittent claudication, including in the arms, are the most common peripheral vascular manifestations of PXE. Often there is asymmetry in blood pressure measured in both arms. Studies have shown that low ankle brachial index (ABI) is common in PXE, being found in as many as 44 percent of affected adults [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Ankle-brachial index'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension secondary to renovascular stenosis is also common in PXE and is an additional risk factor for cardiovascular morbidity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premature coronary artery disease, although less common than peripheral arterial disease, is one of the more serious vascular complications of PXE. Rare cases of childhood or adolescent angina and myocardial infarction (separate from those seen with generalized arterial calcification of infancy [GACI]) have been reported [<a href="#rid31">31</a>]. Heterozygous carriers of the <em>ABCC6</em> variant p.R1141X, most common in the United States and Europe, have been shown to have an increased risk of coronary artery disease [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrovascular disease, including multi-infarct dementia, minor strokes, or transient ischemic attacks, has been reported in PXE [<a href="#rid33">33,34</a>]. In a French cohort of 239 PXE cases, the prevalence of neurovascular manifestations was 10 percent [<a href="#rid35">35</a>]. In a Dutch cohort of 100 patients with PXE, the estimated risk for ischemic stroke under the age of 65 years was nearly four times higher than in the general population (relative risk 3.6; 95% CI 3.3-4.0) [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H3467366543"><span class="h2">Gastrointestinal system</span><span class="headingEndMark"> — </span>Rarely, narrowing of the mesenteric artery or its branches can cause intestinal angina, which presents as postprandial acute, crampy abdominal pain (see  <a class="medical medical_review" href="/z/d/html/2563.html" rel="external">"Chronic mesenteric ischemia", section on 'Symptomatic'</a>). Acute upper gastrointestinal bleeding thought to be due to arterial stenosis involving the blood supply to the stomach has also been reported [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1272519299"><span class="h2">Clinical presentation in children</span><span class="headingEndMark"> — </span>The clinical presentation is children is usually limited to typical skin changes in the vast majority of cases. In the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pxe.org%2Fregistry&amp;token=CSpcrfAPrwUHhoFHX8c%2BvT1wiDNGhGrZqGr0fKuJ3k8TgsbfZ%2B3vZ4LGxYuV5Y6S&amp;TOPIC_ID=15468" target="_blank">PXE International registry</a> (unpublished data), 92 percent of patients diagnosed during childhood reported that skin changes on the neck were the earliest sign of PXE. "Peau d'orange" was the earliest ocular finding, while angioid streaks were not detected until a mean age of 14 years. Children rarely have signs or symptoms of cardiovascular disease other than asymmetric peripheral pulses. However, there are isolated case reports of myocardial infarction, angina, intermittent claudication, and upper gastrointestinal bleeding in children with PXE [<a href="#rid37">37-41</a>].</p><p class="headingAnchor" id="H1281847887"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Biopsy of lesional skin typically shows calcification of clumped, fragmented elastic fibers in the mid-dermis. Although it may be possible in many instances to make the diagnosis on hematoxylin and eosin-stained sections (<a class="graphic graphic_picture graphicRef129962" href="/z/d/graphic/129962.html" rel="external">picture 8</a>), specific stains for elastic tissue (eg, Weigert or Verhoeff-Van Gieson stains (<a class="graphic graphic_picture graphicRef129963" href="/z/d/graphic/129963.html" rel="external">picture 9</a>)) and for calcium (eg, von Kossa or alizarin red stains (<a class="graphic graphic_picture graphicRef129964" href="/z/d/graphic/129964.html" rel="external">picture 10</a>)) are confirmatory. There are histopathologic mimickers of PXE, including calciphylaxis, occupational exposure to sodium nitrate (saltpeter), and hyperphosphatemia in patients on dialysis, but there is usually no diagnostic confusion in these cases.</p><p class="headingAnchor" id="H546027388"><span class="h1">IMAGING FINDINGS</span><span class="headingEndMark"> — </span>In patients with PXE, imaging studies may reveal incidental findings related to elastic fiber calcification. In two studies, diffuse testicular microcalcifications were detected by ultrasonography in nearly all males with PXE, while a significant number of carriers showed focal microcalcifications [<a href="#rid42">42,43</a>]. Microcalcifications in the liver, kidney, or spleen were found in 59 percent of patients and 25 percent of carriers [<a href="#rid42">42,43</a>]. Some of the changes seen on ultrasonography, particularly in the testis, can be found in children with PXE and can even precede the cutaneous signs [<a href="#rid42">42,44,45</a>]. Cutaneous and vascular microcalcifications have also been found in mammograms [<a href="#rid46">46</a>]. Radiologists should be aware of these findings in females with PXE, as they can be misinterpreted as a sign of cancer, leading to unnecessary biopsy.</p><p class="headingAnchor" id="H1742908234"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PXE can be challenging, due to its late onset and the subtle and asymptomatic nature of early skin, eye, and vascular manifestations. It is common for diagnosis to be delayed. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H3712755832"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Clinical diagnostic criteria for PXE were proposed at a consensus conference in 1992, antedating the discovery of the causative gene [<a href="#rid47">47</a>]. An update was suggested in 2010 with criteria including clinical signs as well as molecular testing for definite, probable, and possible diagnosis of PXE [<a href="#rid48">48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major diagnostic criteria</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pseudoxanthomatous papules and plaques on the neck and flexural creases</p><p class="bulletIndent3"><span class="glyph">-</span>Histopathology showing calcification of clumped, pleomorphic elastic fibers in mid- or lower dermis ("elastorrhexis")</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eye:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One or more angioid streaks &gt;1 disc diameter in length</p><p class="bulletIndent3"><span class="glyph">-</span>"Peau d'orange"</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – Two allelic pathogenic variants in <em>ABCC6</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor diagnostic criteria</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Definite PXE in a first-degree relative (sibling, parent, or child [especially if there is parental consanguinity in the latter two instances])</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Finding of pathogenic mutation on only one allele on genetic testing</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histopathologic changes of PXE on nonlesional skin (no visible skin lesions)</p><p></p><p>A diagnosis of <strong>definite PXE</strong> is based on major criteria and requires <strong>at least two</strong><strong><em> </em></strong>of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Two major skin criteria</p><p class="bulletIndent1"><span class="glyph">●</span>One major ocular criterion</p><p class="bulletIndent1"><span class="glyph">●</span>Two allelic pathogenic mutations in <em>ABCC6</em></p><p></p><p>Minor criteria may be help in diagnosing <strong>probable</strong> or <strong>possible</strong><em> </em><strong>PXE</strong> but are insufficient for a definitive diagnosis of<em> </em>PXE if either only two major skin criteria or only one major ocular criterion are present. However, given the late onset of PXE and its virtually 100 percent penetrance, the finding of either a major ocular criterion or two major cutaneous criteria in an individual who has an affected first-degree relative confers a nearly 100 percent probability of definite PXE.</p><p class="headingAnchor" id="H3374258243"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>The finding of homozygosity or compound heterozygosity for two pathogenic variants in <em>ABCC6</em> is considered the gold standard for the diagnosis of PXE. Several laboratories worldwide perform genetic testing for mutations and deletions in <em>ABCC6</em> using either Sanger sequencing or next-generation sequencing approaches as part of panels targeting genes associated with retinal diseases or connective tissue disorders [<a href="#rid1">1</a>]. Sensitivity of these tests is up to 97 percent.</p><p>In clinical practice, genetic testing is rarely necessary for definitive diagnosis. In many cases, the diagnosis is based on the finding of typical skin lesions with histopathologic demonstration of elastic fiber calcification in the mid-dermis <strong>and</strong> characteristic retinal lesions. However, genetic testing is useful in select situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Presymptomatic diagnosis in families with history of PXE [<a href="#rid49">49</a>]. As an example, for unaffected children who have a sibling with definite PXE, genetic testing can be of value in early, presymptomatic diagnosis PXE, especially if the causative mutations are already known. However, in the absence of any effective treatment or strategy to slow the progress of the disease in humans, presymptomatic diagnosis may raise ethical concerns. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with limited clinical manifestations. In patients with isolated angioid streaks, without typical skin lesions and without family history of PXE in a first-degree relative, genetic testing can be of value in confirming or excluding the diagnosis.</p><p></p><p>In cases in which the diagnosis of PXE has been established clinically but no mutations in <em>ABCC6</em> have been found on genetic testing, it might be of value to screen for mutations in <em>ENPP1</em> and <em>GGCX</em>, depending on the phenotype. An uncommon situation arises when PXE is suspected but no causative <em>ABCC6</em> mutations are found on genetic testing. In these cases, beta-thalassemia or related hemoglobinopathy should be ruled out first. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3256074875"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of PXE includes heritable and acquired disorders that phenotypically resemble PXE [<a href="#rid1">1,2,6,13,50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heritable conditions</strong> – Heritable conditions that share cutaneous, ocular, and vascular features of PXE but are associated with distinct gene defects and presumably different pathomechanisms include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PXE/cutis laxa-like overlapping phenotype with multiple coagulation factor deficiency</strong> – PXE-cutis laxa-like phenotype with multiple coagulation factor deficiency presents with overlapping cutaneous and ocular features of PXE and cutis laxa and deficiency in vitamin K-dependent coagulation factors [<a href="#rid3">3</a>]. This disorder is caused by variants in the <em>GGCX</em> gene, encoding gamma-glutamyl-carboxylase, but the precise pathomechanism has not been elucidated [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Familial tumoral calcinosis</strong> – Familial tumoral calcinosis is a rare, autosomal recessive, ectopic mineralization disorder. The hyperphosphatemic forms are caused by variants in any one of three genes (<em>GALNT3</em>, <em>KL</em>, and <em>FGF23</em>) and are characterized by ectopic calcification of periarticular soft tissue<em>.</em> The normophosphatemic form (MIM #610455) is caused by compound heterozygous mutations in <em>SAMD9</em> and presents with extensive cutaneous and mucosal calcium deposition [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/828.html" rel="external">"Overview of the causes and treatment of hyperphosphatemia", section on 'Familial tumoral calcinosis'</a> and  <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">"Calcinosis cutis: Etiology and patient evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pseudo-PXE related to hemoglobinopathy</strong> – Skin manifestations resembling those seen in PXE have been described in some patients with inherited hemoglobinopathies, most often beta-thalassemia and sickle cell disease, in the absence of <em>ABCC6</em> mutations, hypothetically due to epigenetic factors downregulating the expression of <em>ABCC6</em> [<a href="#rid55">55</a>]. However, rare variants of <em>ABCC6</em> and <em>ENPP1</em> genes have been detected in a few patients with thalassemia and clinical skin and eye findings of PXE, suggesting that in some cases PXE and thalassemia can co-occur [<a href="#rid51">51,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a> and  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Angioid streaks can also occur in Marfan syndrome and Ehlers–Danlos syndromes. (See  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a> and  <a class="medical medical_review" href="/z/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired skin disorders</strong> – Acquired skin lesions that resemble PXE papules include [<a href="#rid57">57</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>White fibrous papulosis of the neck [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Papules associated with solar elastosis (<a class="graphic graphic_picture graphicRef61033" href="/z/d/graphic/61033.html" rel="external">picture 11</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late-onset focal dermal elastosis [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Papules associated with chronic <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> therapy [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Perforating calcific elastosis, a rare, acquired skin disease mainly affecting the periumbilical region in multiparous women [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acquired angioid streak-like retinal lesions can be seen in severe myopia and age-related macular degeneration.</p><p></p><p class="headingAnchor" id="H1156121437"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no effective treatment to halt or prevent the systemic mineralization in PXE. A multidisciplinary approach is necessary for the management of the major ocular, vascular, and cutaneous manifestations of PXE [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3367774527"><span class="h2">Ocular manifestations</span><span class="headingEndMark"> — </span>Major ocular complication associated with PXE (ie, loss of visual acuity secondary to bleeding or leakage from neovascularization and blindness) can be averted by timely intravitreal injections of vascular endothelial growth factor (VEGF) antagonists (eg, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10337" href="/z/d/drug information/10337.html" rel="external">ranibizumab</a>, <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>). In a few small clinical studies, intravitreal anti-VEGFs were associated with stabilization or improvement in the best corrected visual acuity and central macular thickness [<a href="#rid62">62-67</a>].</p><p>Patients with PXE need long-term, close follow-up by a specialist in retinal diseases. In-home use of an Amsler grid to self-monitor for distortions in central vision is also recommended. Moreover, as blunt ocular and possibly head trauma can precipitate neovascularization and subretinal hemorrhage, <strong>protection from external head and ocular trauma</strong> and limited participation in contact and racquet sports are critical for prevention of these complications in patients with PXE.</p><p class="headingAnchor" id="H1623806327"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>Plastic surgery is sometimes helpful in improving the appearance of lax skin, particularly in the neck, axillae, and groin. However, it does not reverse the development of pseudoxanthomatous skin changes. In addition, laxity may recur and require follow-up surgical correction. Wound healing is thought to be normal in PXE. Due to the depth of the dystrophic changes in elastic tissue, laser treatment is not effective in managing PXE-related skin changes. Similarly, topical treatments, such as corticosteroids and retinoids, are not effective.</p><p class="headingAnchor" id="H1571623276"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>A retrospective study of<strong> </strong>nearly 800 pregnancies found no evidence for significantly increased fetal loss or adverse reproductive outcomes in PXE. Gastric bleeding, previously thought to be a major risk in pregnant women with PXE, was found to be much lower than previously thought. Although some patients reported worsening of skin manifestations during pregnancy, this was uncommon. There was no correlation between the number of pregnancies or ever having been pregnant with ultimate severity of skin, eye, or cardiovascular manifestations. Most pregnancies in women with PXE appear to be uncomplicated, and there is no basis for advising women with PXE against pregnancy [<a href="#rid68">68</a>]. However, pregnant women with retinal neovascularization may need to consider cesarean section if there is active leakage around the time of delivery and should be closely monitored by retinal specialists. Women with pregnancy-related hypertension may need care by a maternal-fetal specialist.</p><p class="headingAnchor" id="H2482028970"><span class="h2">Prevention of vascular and systemic mineralization</span><span class="headingEndMark"> — </span>There is no definite therapeutic approach for the prevention of systemic and particularly vascular calcification in PXE. However, considering the vascular involvement in PXE, regular exercise and a cardio-protective diet should be encouraged. The patients should be monitored for their serum lipid profiles, and hyperlipidemia should be treated with cholesterol-lowering drugs. Finally, cigarette smoking should be strongly discouraged as it may worsen intermittent claudication. (See  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>Research aimed at treatment development has been focusing either on restoration of inorganic pyrophosphate (PPi) levels in plasma or prevention of calcium hydroxyapatite deposition by PPi-independent means [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral PPi</strong> – After initial demonstration of PPi deficiency in patients with PXE, it was suggested that PPi plasma levels could be restored by oral administration of PPi.</p><p></p><p class="bulletIndent1">Although early studies stated that PPi cannot be absorbed by the intestine due to rapid degradation by intestinal phosphatases, subsequent studies have documented that a small percentage of ingested PPi gets absorbed and increases the levels of PPi in patients with PXE [<a href="#rid69">69</a>]. However, a drawback of this approach is that the half-life of PPi is relatively short (ie, approximately 42 minutes). Phase 2 clinical trials are underway to evaluate the efficacy of slow-release PPi compounds (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04868578&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwNqBnVml7Zx08mGtyUnFnmT0siKgOjBVPWCIsWZxMEpw%3D%3D&amp;TOPIC_ID=15468" target="_blank">NCT04868578</a>) and drugs inhibiting tissue-nonspecific alkaline phosphatase (TNAP; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05569252&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwBNrc%2B82eHSN3926JnhLPHFV6vw0pSTzCj5XpBMG8cNg%3D%3D&amp;TOPIC_ID=15468" target="_blank">NCT05569252</a>), thus prolonging the half-life of PPi.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">Lansoprazole</a>, a proton pump inhibitor, has partial TNAP inhibitory activity. A double-blind, crossover study showed a small but statistically significant rise in PPi levels after eight weeks of 30 mg lansoprazole daily, but its clinical significance is unknown [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bisphosphonates</strong> – The TEMP trial evaluated the efficacy of <a class="drug drug_general" data-topicid="8426" href="/z/d/drug information/8426.html" rel="external">etidronate</a>, a first-generation bisphosphonate with relatively high antimineralization activity as compared with antiosteoclastic activity, for the prevention of ectopic mineralization in PXE [<a href="#rid71">71</a>]. In this study that included 74 patients with PXE and leg arterial calcifications treated with etidronate (cyclical 20 mg/kg for 2 weeks every 12 weeks) or placebo for 12 months, etidronate reduced arterial calcification in the lower extremities by 4 percent, while it increased in the placebo group by 8 percent, as measured by computed tomography. Fewer subretinal neovascularization events occurred in the etidronate group compared with the placebo group.</p><p></p><p class="bulletIndent1">A post-hoc, prespecified analysis of the TEMP trial showed that after one year of treatment, <a class="drug drug_general" data-topicid="8426" href="/z/d/drug information/8426.html" rel="external">etidronate</a> halted the progression of calcification in multiple vascular beds (carotid siphon, common carotid artery, thoracic and abdominal aorta, iliac arteries, and the femoropopliteal and crural arteries), with the exception of the coronary arteries [<a href="#rid72">72</a>]. However, further research is needed to assess the long-term safety and efficacy of etidronate on clinical outcomes in PXE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary magnesium</strong> – Previous studies in animal models of PXE demonstrated that increasing magnesium content of the diet of PXE prevented the ectopic mineralization and reduced carotid intima-media thickness [<a href="#rid73">73,74</a>]. Based on these observations, a randomized trial that included 44 patients with PXE evaluated the efficacy of dietary <a class="drug drug_general" data-topicid="9583" href="/z/d/drug information/9583.html" rel="external">magnesium oxide</a> (MgO) for the treatment of PXE [<a href="#rid75">75</a>]. Treatment consisted of twice-daily 800 mg MgO (500 mg elemental magnesium) or placebo for one year. At one year, a nonstatistically significant decrease in calcification of the skin elastic fibers was noted in the magnesium group, as assessed with a 10-point numeric grading score on skin biopsies stained with Verhoeff-Van Gieson and Von-Kossa stains. Larger studies are needed to confirm the efficacy and safety of magnesium supplementation for PXE. The recommendation of the US Food and Drug Administration (FDA) for daily magnesium intake is 420 mg for an adult male and 320 mg for an adult female.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phosphate binders</strong> – The potential efficacy of an intestinal phosphate binder, <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">sevelamer</a> hydrochloride, was assessed in a randomized trial that included 40 patients with PXE [<a href="#rid76">76</a>]. Patients received oral sevelamer hydrochloride 800 mg three times daily or placebo for one year. During the first year of treatment, a decrease in the calcium score of the skin elastic fibers was noted. The mean clinical score of skin lesions also improved while no deterioration of eye involvement was noted. Complicating the interpretation of these data was the fact that both the placebo and the active drug preparation contained magnesium stearate, which may have played a confounding role in this study. Larger, better controlled clinical trials are required to assess the role of phosphate binders in treatment of PXE.</p><p></p><p>Although the results of these studies appear promising, none of these therapies is yet in widely accepted clinical use.</p><p class="headingAnchor" id="H3571973626"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>PXE mode of inheritance is autosomal recessive. Genetic testing is recommended for the parents of a proband to confirm that each parent is heterozygous for an <em>ABCC6 </em>pathogenic variant and to allow reliable assessment of risk for subsequent pregnancies [<a href="#rid1">1</a>]. If parents of an affected child are confirmed heterozygous for an <em>ABCC6 </em>pathogenic variant, each sibling has at conception a 25 percent probability of being affected, a 50 percent probability of being an asymptomatic carrier, and a 25 percent probability of being unaffected and not a carrier [<a href="#rid1">1</a>]. Since siblings of an affected patient are at risk, they should be offered screening by examination and clinical history and, if indicated, genetic testing.</p><p class="headingAnchor" id="H762342058"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis</strong> – Pseudoxanthoma elasticum (PXE; MIM #264800) is a rare, late-onset, heritable disorder characterized by ectopic mineralization and fragmentation of elastic fibers in the skin, eye, vascular, and gastrointestinal system. PXE is caused by homozygous or compound heterozygous pathogenic variants in the <em>ABCC6</em> gene, encoding a transporter protein expressed primarily in the liver and involved in the extracellular conversion of ATP to AMP and inorganic pyrophosphate (PPi), a powerful antimineralization factor. (See <a class="local">'Genetics'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous manifestations</strong> – Early cutaneous and ocular findings are subtle and are in most cases not noticed until the second or third decades of life. The primary skin lesions are papules darker than the person's natural skin tone, initially located on the side of the neck (<a class="graphic graphic_picture graphicRef129952 graphicRef129957" href="/z/d/graphic/129952.html" rel="external">picture 1A-B</a>) and later in the axillae (<a class="graphic graphic_picture graphicRef129953" href="/z/d/graphic/129953.html" rel="external">picture 2</a>) and other flexural areas, chest, and abdomen. Ultimately, the affected skin becomes lax and redundant (<a class="graphic graphic_picture graphicRef129954 graphicRef129958" href="/z/d/graphic/129954.html" rel="external">picture 3A-B</a>). (See <a class="local">'Skin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular manifestations</strong> – Angioid streaks, named because of their resemblance to retinal vessels, are the most characteristic eye finding in PXE (<a class="graphic graphic_picture graphicRef129955" href="/z/d/graphic/129955.html" rel="external">picture 4</a>). As the disease progresses, choroidal neovascularization occurs. Leakage of serum or blood from these vessels results in focal retinal detachments (<a class="graphic graphic_picture graphicRef129960" href="/z/d/graphic/129960.html" rel="external">picture 6</a>) and distorted vision. (See <a class="local">'Eye'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular manifestations</strong> – Diminution or loss of peripheral pulses and early onset of intermittent claudication are the most common peripheral vascular manifestations of PXE. Additional vascular complications of PXE include renovascular hypertension, premature coronary artery disease, and cerebrovascular disease. Involvement of the mesenteric artery and its branches may be associated with intestinal angina and upper gastrointestinal bleeding. (See <a class="local">'Cardiovascular system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The finding of homozygosity or compound heterozygosity for two pathogenic mutations in <em>ABCC6</em> on genetic testing is considered the gold standard for diagnosis of PXE. In most cases, however, the diagnosis of PXE is clinical, based on the finding of typical skin lesions with histopathologic demonstration of elastic fiber calcification in the mid-dermis <strong>and </strong>angioid streaks in the retina. Due to the late onset and subtle and asymptomatic nature of early skin, eye, and vascular manifestations, the diagnosis is often delayed. (See <a class="local">'Diagnostic criteria'</a> above and <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no effective treatment to halt or prevent the systemic mineralization in PXE. Experimental therapies for the prevention of calcium hydroxyapatite deposition, such as oral PPi, first-generation bisphosphonates, and dietary supplementation of magnesium, have been evaluated in a few clinical studies with varying results. However, none are widely accepted yet for clinical use. (See <a class="local">'Prevention of vascular and systemic mineralization'</a> above.)</p><p></p><p class="bulletIndent1">A multidisciplinary approach is necessary for the management of the major ocular, vascular, and cutaneous manifestations of PXE. Intravitreal injections of vascular endothelial growth factor (VEGF) antagonists (eg, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10337" href="/z/d/drug information/10337.html" rel="external">ranibizumab</a>, <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>) have been reported as effective for the stabilization or improvement of visual acuity in patients with angioid streaks and choroidal neovascularization. (See <a class="local">'Cutaneous manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Plastic surgery may be helpful in improving the appearance of lax skin, particularly in the neck, axillae, and groin. However, laxity may recur and require follow-up surgical corrections. (See <a class="local">'Cutaneous manifestations'</a> above.)</p><p></p><p class="headingAnchor" id="H3466980136"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jouni Uitto, MD, PhD (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Terry SF, Uitto J. Pseudoxanthoma elasticum. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li class="breakAll">Reynolds SD, Bercovitch L. Pseudoxanthoma elasticum and cutis laxa. In: Harper's Textbook of Pediatric Dermatology, 4th ed, Hoeger P, Kinsler V, Yan A (Eds), Wiley, 2019.</li><li><a class="nounderline abstract_t">Luo H, Faghankhani M, Cao Y, et al. Molecular Genetics and Modifier Genes in Pseudoxanthoma Elasticum, a Heritable Multisystem Ectopic Mineralization Disorder. J Invest Dermatol 2021; 141:1148.</a></li><li><a class="nounderline abstract_t">Neldner KH. Pseudoxanthoma elasticum. Clin Dermatol 1988; 6:1.</a></li><li><a class="nounderline abstract_t">Le Saux O, Beck K, Sachsinger C, et al. Evidence for a founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa. Hum Genet 2002; 111:331.</a></li><li><a class="nounderline abstract_t">Chassaing N, Martin L, Calvas P, et al. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet 2005; 42:881.</a></li><li><a class="nounderline abstract_t">Bergen AA, Plomp AS, Schuurman EJ, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 2000; 25:228.</a></li><li><a class="nounderline abstract_t">Szeri F, Miko A, Navasiolava N, et al. The pathogenic c.1171A&gt;G (p.Arg391Gly) and c.2359G&gt;A (p.Val787Ile) ABCC6 variants display incomplete penetrance causing pseudoxanthoma elasticum in a subset of individuals. Hum Mutat 2022; 43:1872.</a></li><li><a class="nounderline abstract_t">Ringpfeil F, McGuigan K, Fuchsel L, et al. Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity. J Invest Dermatol 2006; 126:782.</a></li><li><a class="nounderline abstract_t">Pfendner EG, Vanakker OM, Terry SF, et al. Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J Med Genet 2007; 44:621.</a></li><li><a class="nounderline abstract_t">Li Q, Schumacher W, Jablonski D, et al. Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene. Br J Dermatol 2012; 166:1107.</a></li><li><a class="nounderline abstract_t">Nitschke Y, Baujat G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet 2012; 90:25.</a></li><li><a class="nounderline abstract_t">Li Q, van de Wetering K, Uitto J. Pseudoxanthoma Elasticum as a Paradigm of Heritable Ectopic Mineralization Disorders: Pathomechanisms and Treatment Development. Am J Pathol 2019; 189:216.</a></li><li class="breakAll">Ferreira C, Ziegler S, Gahl WA. Generalized arterial calcification of infancy. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Markello TC, Pak LK, St Hilaire C, et al. Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol Genet Metab 2011; 103:44.</a></li><li><a class="nounderline abstract_t">Jansen RS, Küçükosmanoglu A, de Haas M, et al. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A 2013; 110:20206.</a></li><li><a class="nounderline abstract_t">Jansen RS, Duijst S, Mahakena S, et al. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol 2014; 34:1985.</a></li><li><a class="nounderline abstract_t">Van Gils M, Depauw J, Coucke PJ, et al. Inorganic Pyrophosphate Plasma Levels Are Decreased in Pseudoxanthoma Elasticum Patients and Heterozygous Carriers but Do Not Correlate with the Genotype or Phenotype. J Clin Med 2023; 12.</a></li><li><a class="nounderline abstract_t">Kozák E, Bartstra JW, de Jong PA, et al. Plasma Level of Pyrophosphate Is Low in Pseudoxanthoma Elasticum Owing to Mutations in the ABCC6 Gene, but It Does Not Correlate with ABCC6 Genotype. J Clin Med 2023; 12.</a></li><li><a class="nounderline abstract_t">Rutsch F, Schauerte P, Kalhoff H, et al. Low levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a boy with idiopathic infantile arterial calcification. Acta Paediatr 2000; 89:1265.</a></li><li><a class="nounderline abstract_t">St Hilaire C, Ziegler SG, Markello TC, et al. NT5E mutations and arterial calcifications. N Engl J Med 2011; 364:432.</a></li><li><a class="nounderline abstract_t">Li Q, Price TP, Sundberg JP, Uitto J. Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations. Cell Cycle 2014; 13:2609.</a></li><li><a class="nounderline abstract_t">Luo H, Li Q, Cao Y, Uitto J. Therapeutics Development for Pseudoxanthoma Elasticum and Related Ectopic Mineralization Disorders: Update 2020. J Clin Med 2020; 10.</a></li><li><a class="nounderline abstract_t">Uitto J, Pulkkinen L, Ringpfeil F. Molecular genetics of pseudoxanthoma elasticum: a metabolic disorder at the environment-genome interface? Trends Mol Med 2001; 7:13.</a></li><li><a class="nounderline abstract_t">Uitto J, Jiang Q, Váradi A, et al. PSEUDOXANTHOMA ELASTICUM: DIAGNOSTIC FEATURES, CLASSIFICATION, AND TREATMENT OPTIONS. Expert Opin Orphan Drugs 2014; 2:567.</a></li><li><a class="nounderline abstract_t">Naouri M, Boisseau C, Bonicel P, et al. Manifestations of pseudoxanthoma elasticum in childhood. Br J Dermatol 2009; 161:635.</a></li><li><a class="nounderline abstract_t">Georgalas I, Papaconstantinou D, Koutsandrea C, et al. Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 2009; 5:81.</a></li><li><a class="nounderline abstract_t">Campens L, Vanakker OM, Trachet B, et al. Characterization of cardiovascular involvement in pseudoxanthoma elasticum families. Arterioscler Thromb Vasc Biol 2013; 33:2646.</a></li><li><a class="nounderline abstract_t">Leftheriotis G, Kauffenstein G, Hamel JF, et al. The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum. PLoS One 2014; 9:e96003.</a></li><li><a class="nounderline abstract_t">Lefthériotis G, Omarjee L, Le Saux O, et al. The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. Front Genet 2013; 4:4.</a></li><li><a class="nounderline abstract_t">Li Q, Baker J, Kowalczyk J, et al. Paediatric pseudoxanthoma elasticum with cardiovascular involvement. Br J Dermatol 2013; 169:1148.</a></li><li><a class="nounderline abstract_t">Köblös G, Andrikovics H, Prohászka Z, et al. The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease. Genet Test Mol Biomarkers 2010; 14:75.</a></li><li><a class="nounderline abstract_t">Kauw F, Kranenburg G, Kappelle LJ, et al. Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature. J Neurol Sci 2017; 373:167.</a></li><li><a class="nounderline abstract_t">van den Berg JS, Hennekam RC, Cruysberg JR, et al. Prevalence of symptomatic intracranial aneurysm and ischaemic stroke in pseudoxanthoma elasticum. Cerebrovasc Dis 2000; 10:315.</a></li><li><a class="nounderline abstract_t">Legrand A, Cornez L, Samkari W, et al. Mutation spectrum in the ABCC6 gene and genotype-phenotype correlations in a French cohort with pseudoxanthoma elasticum. Genet Med 2017; 19:909.</a></li><li><a class="nounderline abstract_t">Spinzi G, Strocchi E, Imperiali G, et al. Pseudoxanthoma elasticum: a rare cause of gastrointestinal bleeding. Am J Gastroenterol 1996; 91:1631.</a></li><li><a class="nounderline abstract_t">Kieć-Wilk B, Surdacki A, Dembińska-Kieć A, et al. Acute myocardial infarction and a new ABCC6 mutation in a 16-year-old boy with pseudoxanthoma elasticum. Int J Cardiol 2007; 116:261.</a></li><li><a class="nounderline abstract_t">Bete JM, Banas JS Jr, Moran J, et al. Coronary artery disease in an 18 year old with pseudoxanthoma elasticum: successful surgical therapy. Am J Cardiol 1975; 36:515.</a></li><li><a class="nounderline abstract_t">Kévorkian JP, Masquet C, Kural-Ménasché S, et al. New report of severe coronary artery disease in an eighteen-year-old girl with pseudoxanthoma elasticum. Case report and review of the literature. Angiology 1997; 48:735.</a></li><li><a class="nounderline abstract_t">Barrie L, Mazereeuw-Hautier J, Garat H, Bonafe JL. [Early pseudoxanthoma elasticum with severe cardiovascular involvement]. Ann Dermatol Venereol 2004; 131:275.</a></li><li><a class="nounderline abstract_t">Antiga E, Melani L, Caproni M, Fabbri P. An unusual cause of gastrointestinal bleeding in a young girl. CMAJ 2006; 175:583.</a></li><li><a class="nounderline abstract_t">Bercovitch RS, Januario JA, Terry SF, et al. Testicular microlithiasis in association with pseudoxanthoma elasticum. Radiology 2005; 237:550.</a></li><li><a class="nounderline abstract_t">Vanakker OM, Voet D, Petrovic M, et al. Visceral and testicular calcifications as part of the phenotype in pseudoxanthoma elasticum: ultrasound findings in Belgian patients and healthy carriers. Br J Radiol 2006; 79:221.</a></li><li><a class="nounderline abstract_t">Pinto K, Pena RD. Testicular calcifications in pseudoxanthoma elasticum. J Urol 2004; 171:1898.</a></li><li><a class="nounderline abstract_t">Goede J, Hack WW, Sijstermans K, Pierik FH. Testicular microlithiasis in a 2-year-old boy with pseudoxanthoma elasticum. J Ultrasound Med 2008; 27:1503.</a></li><li><a class="nounderline abstract_t">Bercovitch L, Schepps B, Koelliker S, et al. Mammographic findings in pseudoxanthoma elasticum. J Am Acad Dermatol 2003; 48:359.</a></li><li><a class="nounderline abstract_t">Lebwohl M, Neldner K, Pope FM, et al. Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol 1994; 30:103.</a></li><li><a class="nounderline abstract_t">Plomp AS, Toonstra J, Bergen AA, et al. Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A 2010; 152A:1049.</a></li><li><a class="nounderline abstract_t">Li Q, Török L, Kocsis L, Uitto J. Mutation analysis (ABCC6) in a family with pseudoxanthoma elasticum: presymptomatic testing with prognostic implications. Br J Dermatol 2010; 163:641.</a></li><li><a class="nounderline abstract_t">Germain DP. Pseudoxanthoma elasticum. Orphanet J Rare Dis 2017; 12:85.</a></li><li><a class="nounderline abstract_t">Li D, Ryu E, Saeidian AH, et al. GGCX mutations in a patient with overlapping pseudoxanthoma elasticum/cutis laxa-like phenotype. Br J Dermatol 2021; 184:1170.</a></li><li><a class="nounderline abstract_t">Vanakker OM, Martin L, Gheduzzi D, et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol 2007; 127:581.</a></li><li><a class="nounderline abstract_t">Hershkovitz D, Gross Y, Nahum S, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. J Invest Dermatol 2011; 131:662.</a></li><li><a class="nounderline abstract_t">Chefetz I, Ben Amitai D, Browning S, et al. Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein. J Invest Dermatol 2008; 128:1423.</a></li><li><a class="nounderline abstract_t">Hamlin N, Beck K, Bacchelli B, et al. Acquired Pseudoxanthoma elasticum-like syndrome in beta-thalassaemia patients. Br J Haematol 2003; 122:852.</a></li><li><a class="nounderline abstract_t">Boraldi F, Lofaro FD, Costa S, et al. Rare Co-occurrence of Beta-Thalassemia and Pseudoxanthoma elasticum: Novel Biomolecular Findings. Front Med (Lausanne) 2019; 6:322.</a></li><li><a class="nounderline abstract_t">Andrés-Ramos I, Alegría-Landa V, Gimeno I, et al. Cutaneous Elastic Tissue Anomalies. Am J Dermatopathol 2019; 41:85.</a></li><li><a class="nounderline abstract_t">Dokic Y, Tschen J. White Fibrous Papulosis of the Axillae and Neck. Cureus 2020; 12:e7635.</a></li><li><a class="nounderline abstract_t">Wang AR, Fonder MA, Telang GH, et al. Late-onset focal dermal elastosis: an uncommon mimicker of pseudoxanthoma elasticum. J Cutan Pathol 2012; 39:957.</a></li><li><a class="nounderline abstract_t">Poon E, Mason GH, Oh C. Clinical and histological spectrum of elastotic changes induced by penicillamine. Australas J Dermatol 2002; 43:147.</a></li><li><a class="nounderline abstract_t">Lopes LC, Lobo L, Bajanca R. Perforating calcific elastosis. J Eur Acad Dermatol Venereol 2003; 17:206.</a></li><li><a class="nounderline abstract_t">Finger RP, Charbel Issa P, Schmitz-Valckenberg S, et al. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum. Retina 2011; 31:1268.</a></li><li><a class="nounderline abstract_t">Myung JS, Bhatnagar P, Spaide RF, et al. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2010; 30:748.</a></li><li><a class="nounderline abstract_t">Bhatnagar P, Freund KB, Spaide RF, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2007; 27:897.</a></li><li><a class="nounderline abstract_t">Alagöz C, Alagöz N, Özkaya A, et al. INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANE DUE TO ANGIOID STREAKS. Retina 2015; 35:2001.</a></li><li><a class="nounderline abstract_t">Battaglia Parodi M, Romano F, Marchese A, et al. Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2019; 257:273.</a></li><li><a class="nounderline abstract_t">Gliem M, Birtel J, Herrmann P, et al. Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study. Graefes Arch Clin Exp Ophthalmol 2020; 258:311.</a></li><li><a class="nounderline abstract_t">Bercovitch L, Leroux T, Terry S, Weinstock MA. Pregnancy and obstetrical outcomes in pseudoxanthoma elasticum. Br J Dermatol 2004; 151:1011.</a></li><li><a class="nounderline abstract_t">Dedinszki D, Szeri F, Kozák E, et al. Oral administration of pyrophosphate inhibits connective tissue calcification. EMBO Mol Med 2017; 9:1463.</a></li><li><a class="nounderline abstract_t">Murcia Casas B, Carrillo Linares JL, Baquero Aranda I, et al. Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial. Int J Mol Sci 2023; 24.</a></li><li><a class="nounderline abstract_t">Kranenburg G, de Jong PA, Bartstra JW, et al. Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. J Am Coll Cardiol 2018; 71:1117.</a></li><li><a class="nounderline abstract_t">Bartstra JW, de Jong PA, Kranenburg G, et al. Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. Atherosclerosis 2020; 292:37.</a></li><li><a class="nounderline abstract_t">Kupetsky EA, Rincon F, Uitto J. Rate of change of carotid intima-media thickness with magnesium administration in Abcc6⁻/⁻ mice. Clin Transl Sci 2013; 6:485.</a></li><li><a class="nounderline abstract_t">Kupetsky-Rincon EA, Li Q, Uitto J. Magnesium reduces carotid intima-media thickness in a mouse model of pseudoxanthoma elasticum: a novel treatment biomarker. Clin Transl Sci 2012; 5:259.</a></li><li><a class="nounderline abstract_t">Rose S, On SJ, Fuchs W, et al. Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial. J Am Acad Dermatol 2019; 81:263.</a></li><li><a class="nounderline abstract_t">Yoo JY, Blum RR, Singer GK, et al. A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol 2011; 65:341.</a></li></ol></div><div id="topicVersionRevision">Topic 15468 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Terry SF, Uitto J. Pseudoxanthoma elasticum. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Reynolds SD, Bercovitch L. Pseudoxanthoma elasticum and cutis laxa. In: Harper's Textbook of Pediatric Dermatology, 4th ed, Hoeger P, Kinsler V, Yan A (Eds), Wiley, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33341249" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular Genetics and Modifier Genes in Pseudoxanthoma Elasticum, a Heritable Multisystem Ectopic Mineralization Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3359381" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384774" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence for a founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894595" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835643" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mutations in ABCC6 cause pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36317459" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The pathogenic c.1171A&gt;G (p.Arg391Gly) and c.2359G&gt;A (p.Val787Ile) ABCC6 variants display incomplete penetrance causing pseudoxanthoma elasticum in a subset of individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410789" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617515" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22229486" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22209248" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30414410" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pseudoxanthoma Elasticum as a Paradigm of Heritable Ectopic Mineralization Disorders: Pathomechanisms and Treatment Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30414410" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pseudoxanthoma Elasticum as a Paradigm of Heritable Ectopic Mineralization Disorders: Pathomechanisms and Treatment Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371928" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24277820" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24969777" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36902680" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inorganic Pyrophosphate Plasma Levels Are Decreased in Pseudoxanthoma Elasticum Patients and Heterozygous Carriers but Do Not Correlate with the Genotype or Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36769695" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Plasma Level of Pyrophosphate Is Low in Pseudoxanthoma Elasticum Owing to Mutations in the ABCC6 Gene, but It Does Not Correlate with ABCC6 Genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083387" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Low levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a boy with idiopathic infantile arterial calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288095" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : NT5E mutations and arterial calcifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25486201" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33396306" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Therapeutics Development for Pseudoxanthoma Elasticum and Related Ectopic Mineralization Disorders: Update 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427982" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Molecular genetics of pseudoxanthoma elasticum: a metabolic disorder at the environment-genome interface?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25383264" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : PSEUDOXANTHOMA ELASTICUM: DIAGNOSTIC FEATURES, CLASSIFICATION, AND TREATMENT OPTIONS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19519828" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Manifestations of pseudoxanthoma elasticum in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436620" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Angioid streaks, clinical course, complications, and current therapeutic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23968982" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Characterization of cardiovascular involvement in pseudoxanthoma elasticum families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24800819" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408347" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746223" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Paediatric pseudoxanthoma elasticum with cardiovascular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19929409" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28131180" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10878438" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence of symptomatic intracranial aneurysm and ischaemic stroke in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28102862" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mutation spectrum in the ABCC6 gene and genotype-phenotype correlations in a French cohort with pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759675" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pseudoxanthoma elasticum: a rare cause of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16854481" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acute myocardial infarction and a new ABCC6 mutation in a 16-year-old boy with pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1081335" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Coronary artery disease in an 18 year old with pseudoxanthoma elasticum: successful surgical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269144" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : New report of severe coronary artery disease in an eighteen-year-old girl with pseudoxanthoma elasticum. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15107747" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : [Early pseudoxanthoma elasticum with severe cardiovascular involvement].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966659" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : An unusual cause of gastrointestinal bleeding in a young girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244264" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Testicular microlithiasis in association with pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498034" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Visceral and testicular calcifications as part of the phenotype in pseudoxanthoma elasticum: ultrasound findings in Belgian patients and healthy carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15076302" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Testicular calcifications in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809961" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Testicular microlithiasis in a 2-year-old boy with pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637915" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mammographic findings in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8277008" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Classification of pseudoxanthoma elasticum: report of a consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20358627" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20491760" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mutation analysis (ABCC6) in a family with pseudoxanthoma elasticum: presymptomatic testing with prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486967" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33000479" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : GGCX mutations in a patient with overlapping pseudoxanthoma elasticum/cutis laxa-like phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110937" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160498" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094730" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930400" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acquired Pseudoxanthoma elasticum-like syndrome in beta-thalassaemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32039214" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rare Co-occurrence of Beta-Thalassemia and Pseudoxanthoma elasticum: Novel Biomolecular Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30688725" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cutaneous Elastic Tissue Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32399367" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : White Fibrous Papulosis of the Axillae and Neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882354" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Late-onset focal dermal elastosis: an uncommon mimicker of pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982575" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical and histological spectrum of elastotic changes induced by penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12705754" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Perforating calcific elastosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21386758" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996818" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17891014" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25996427" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANE DUE TO ANGIOID STREAKS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30470876" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863395" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541079" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pregnancy and obstetrical outcomes in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28701330" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Oral administration of pyrophosphate inhibits connective tissue calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36902331" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519353" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31756632" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330694" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Rate of change of carotid intima-media thickness with magnesium administration in Abcc6⁻/⁻mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22686203" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Magnesium reduces carotid intima-media thickness in a mouse model of pseudoxanthoma elasticum: a novel treatment biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30826287" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496949" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
